Skip to content

Mannkind MNKD Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
Merit Medical Systems logo
Merit Medical SystemsMMSI

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B-50.6%
Enterprise value$1.15B-52.2%
P/E228.5×
P/S3.3×-4.8×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's contract liabilities, non-current?
Mannkind (MNKD) reported contract liabilities, non-current of $38.91M in Q1 2026.
How has Mannkind's contract liabilities, non-current changed year-over-year?
Mannkind's contract liabilities, non-current decreased by 17.9% year-over-year, from $47.36M to $38.91M.
What is the long-term trend for Mannkind's contract liabilities, non-current?
Over 5 years (2020 to 2025), Mannkind's contract liabilities, non-current has grown at a 88.9% compound annual growth rate (CAGR), from $1.66M to $39.98M.